This suggests that SGLT2 inhibition decreases the risk of T2DM and demonstrates that the target gene, SLC5A2, can serve as a genetic tool for the drug target of SGLT2 inhibitors. Here, SLC5A2 is linked to type 2 diabetes mellitus.